Recombinant Human akr1b10

Background

AKR1B10 is primarily expressed in the liver, intestines, and lungs, where it catalyzes the reduction of carbonyl compounds, including aldehydes derived from lipid peroxidation and retinoic acid metabolism. AKR1B10 plays a pivotal role in detoxifying reactive aldehydes, thereby protecting cells from oxidative stress and lipid damage. It also regulates cellular retinoic acid levels, influencing cell proliferation, differentiation, and apoptosis. Overexpression of AKR1B10 is strongly associated with various cancers, particularly hepatocellular carcinoma (HCC), non-small-cell lung cancer (NSCLC), and colorectal cancer, where it enhances tumor progression, chemoresistance, and metastasis. AKR1B10 contributes to drug resistance by metabolizing chemotherapeutic agents and supporting lipid synthesis for tumor growth. Its role in fatty acid biosynthesis links it to metabolic reprogramming in cancer cells, promoting proliferation and survival. AKR1B10 is considered a promising biomarker for cancer diagnosis and prognosis, as well as a therapeutic target for improving cancer treatment outcomes.